Market closed
Cardiff Oncology/$CRDF
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Cardiff Oncology
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
Ticker
$CRDF
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
32
Website
Cardiff Oncology Metrics
BasicAdvanced
$230M
-
-$0.95
1.91
-
Price and volume
Market cap
$230M
Beta
1.91
52-week high
$6.42
52-week low
$1.44
Average daily volume
1.5M
Financial strength
Current ratio
4.737
Quick ratio
4.653
Long term debt to equity
1.982
Total debt to equity
3.414
Management effectiveness
Return on assets (TTM)
-38.33%
Return on equity (TTM)
-67.57%
Valuation
Price to revenue (TTM)
226.989
Price to book
3.4
Price to tangible book (TTM)
3.4
Price to free cash flow (TTM)
-4.507
Growth
Revenue change (TTM)
49.57%
Earnings per share change (TTM)
3.62%
3-year revenue growth (CAGR)
25.87%
3-year earnings per share growth (CAGR)
12.14%
What the Analysts think about Cardiff Oncology
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cardiff Oncology stock.
Cardiff Oncology Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Cardiff Oncology Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Cardiff Oncology News
AllArticlesVideos
Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +
Seeking Alpha·2 months ago
Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning
Seeking Alpha·2 months ago
Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cardiff Oncology stock?
Cardiff Oncology (CRDF) has a market cap of $230M as of January 31, 2025.
What is the P/E ratio for Cardiff Oncology stock?
The price to earnings (P/E) ratio for Cardiff Oncology (CRDF) stock is 0 as of January 31, 2025.
Does Cardiff Oncology stock pay dividends?
No, Cardiff Oncology (CRDF) stock does not pay dividends to its shareholders as of January 31, 2025.
When is the next Cardiff Oncology dividend payment date?
Cardiff Oncology (CRDF) stock does not pay dividends to its shareholders.
What is the beta indicator for Cardiff Oncology?
Cardiff Oncology (CRDF) has a beta rating of 1.91. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.